Largest medical research grant to help ME/CFS and Long COVID research

Griffith News
19 April 2023
https://news.griffith.edu.au/2023/04/19/largest-medical-research-grant-to-help-me-cfs-and-long-covid-research/

Treating Long-COVID Brain Fog With ME/CFS Guidelines

Medscape
27 March 2023
https://www.medscape.com/viewarticle/989887

Cognitive symptoms, commonly referred to as brain fog, are among the most common persistent or new symptoms after COVID-19. Cognitive symptoms are also often reported by patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

An Update on the Uses of Naltrexone in Clinical Practice

Natural Medicine Journal
01 August 2022
https://www.naturalmedicinejournal.com/journal/an-update-on-the-uses-of-naltrexone-in-clinical-practice

Can an Addiction Drug Treat Long Covid?

RollingStone
22 March 2023
https://www.rollingstone.com/culture/culture-features/long-covid-treatment-addiction-drug-1234701573/

Long COVID: major findings, mechanisms and recommendations

Nature reviews: microbiology
13 January 2023
https://www.nature.com/articles/s41579-022-00846-2

Researchers launch trial to treat long COVID with drug used to block effects of opioids

ABC Gold Coast
20 December 2022
https://www.abc.net.au/news/2022-12-21/long-covid-treatment-trial-drug-low-dose-naltrexone/101770626?utm_source=abc_news_web&utm_medium=content_shared&utm_campaign=abc_news_web

Addiction drug shows promise lifting long COVID brain fog, fatigue

Reuters
18 October 2022
https://www.reuters.com/business/healthcare-pharmaceuticals/addiction-drug-shows-promise-lifting-long-covid-brain-fog-fatigue-2022-10-18/

Linda: Welcome to the LDN radio show brought to you by the LDN Research Trust. I'm your host Linda Elsegood.  I have an exciting lineup of guest speakers who are LDN experts in their field. We will be discussing low dose naltrexone and its many uses in autoimmune diseases, cancers, etc. Thank you for joining us.

The LDN 3: To Purchase with discounts before 1st September 2022 Go to ldnresearchtrust.org/ldn-book-3 for full details